vs
AvePoint（AVPT）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
AvePoint的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.5倍（$114.7M vs $75.5M），AvePoint同比增速更快（28.6% vs 27.7%），AvePoint自由现金流更多（$29.0M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 24.0%）
AvePoint是一家总部位于美国新泽西州泽西市的企业，成立于2001年，2020年在纳斯达克上市。公司专注于开发软件产品，为Microsoft 365、谷歌、Salesforce等主流平台提供功能拓展与安全增强解决方案，服务全球各行业客户的数字化协作与数据治理需求。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
AVPT vs PBYI — 直观对比
营收规模更大
AVPT
是对方的1.5倍
$75.5M
营收增速更快
AVPT
高出0.9%
27.7%
自由现金流更多
AVPT
多$14.6M
$14.4M
两年增速更快
PBYI
近两年复合增速
24.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.7M | $75.5M |
| 净利润 | $15.6M | — |
| 毛利率 | 73.6% | 69.3% |
| 营业利润率 | 12.7% | 22.7% |
| 净利率 | 13.6% | — |
| 营收同比 | 28.6% | 27.7% |
| 净利润同比 | 191.1% | — |
| 每股收益（稀释后） | $0.06 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVPTPBYI
| Q4 25 | $114.7M | $75.5M | ||
| Q3 25 | $109.7M | $54.5M | ||
| Q2 25 | $102.0M | $52.4M | ||
| Q1 25 | $93.1M | $46.0M | ||
| Q4 24 | $89.2M | $59.1M | ||
| Q3 24 | $88.8M | $80.5M | ||
| Q2 24 | $78.0M | $47.1M | ||
| Q1 24 | $74.5M | $43.8M |
净利润AVPTPBYI
| Q4 25 | $15.6M | — | ||
| Q3 25 | $13.0M | $8.8M | ||
| Q2 25 | $2.9M | $5.9M | ||
| Q1 25 | $3.6M | $3.0M | ||
| Q4 24 | $-17.2M | — | ||
| Q3 24 | $2.6M | $20.3M | ||
| Q2 24 | $-12.9M | $-4.5M | ||
| Q1 24 | $-2.0M | $-4.8M |
毛利率AVPTPBYI
| Q4 25 | 73.6% | 69.3% | ||
| Q3 25 | 74.4% | 77.7% | ||
| Q2 25 | 74.0% | 76.5% | ||
| Q1 25 | 74.3% | 77.1% | ||
| Q4 24 | 75.4% | 76.4% | ||
| Q3 24 | 76.1% | 63.9% | ||
| Q2 24 | 75.7% | 77.4% | ||
| Q1 24 | 72.6% | 75.5% |
营业利润率AVPTPBYI
| Q4 25 | 12.7% | 22.7% | ||
| Q3 25 | 7.4% | 17.6% | ||
| Q2 25 | 7.0% | 12.7% | ||
| Q1 25 | 3.5% | 8.7% | ||
| Q4 24 | 5.4% | 22.6% | ||
| Q3 24 | 8.6% | 27.4% | ||
| Q2 24 | -2.7% | -4.6% | ||
| Q1 24 | -4.3% | -5.3% |
净利率AVPTPBYI
| Q4 25 | 13.6% | — | ||
| Q3 25 | 11.9% | 16.2% | ||
| Q2 25 | 2.8% | 11.2% | ||
| Q1 25 | 3.8% | 6.5% | ||
| Q4 24 | -19.3% | — | ||
| Q3 24 | 3.0% | 25.2% | ||
| Q2 24 | -16.6% | -9.6% | ||
| Q1 24 | -2.6% | -11.0% |
每股收益（稀释后）AVPTPBYI
| Q4 25 | $0.06 | $0.26 | ||
| Q3 25 | $0.06 | $0.17 | ||
| Q2 25 | $0.01 | $0.12 | ||
| Q1 25 | $0.02 | $0.06 | ||
| Q4 24 | $-0.09 | $0.40 | ||
| Q3 24 | $0.01 | $0.41 | ||
| Q2 24 | $-0.07 | $-0.09 | ||
| Q1 24 | $-0.01 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $481.1M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $478.7M | $130.3M |
| 总资产 | $789.2M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资AVPTPBYI
| Q4 25 | $481.1M | $97.5M | ||
| Q3 25 | $471.6M | $94.4M | ||
| Q2 25 | $430.1M | $96.0M | ||
| Q1 25 | $351.8M | $93.2M | ||
| Q4 24 | $290.9M | $101.0M | ||
| Q3 24 | $250.0M | $96.7M | ||
| Q2 24 | $230.8M | $96.8M | ||
| Q1 24 | $219.3M | $107.2M |
总债务AVPTPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益AVPTPBYI
| Q4 25 | $478.7M | $130.3M | ||
| Q3 25 | $466.8M | $115.3M | ||
| Q2 25 | $443.1M | $104.7M | ||
| Q1 25 | $361.5M | $97.1M | ||
| Q4 24 | $270.9M | $92.1M | ||
| Q3 24 | $215.7M | $71.1M | ||
| Q2 24 | $207.4M | $48.5M | ||
| Q1 24 | $212.7M | $51.0M |
总资产AVPTPBYI
| Q4 25 | $789.2M | $216.3M | ||
| Q3 25 | $743.5M | $202.9M | ||
| Q2 25 | $700.1M | $194.9M | ||
| Q1 25 | $598.8M | $196.2M | ||
| Q4 24 | $519.1M | $213.3M | ||
| Q3 24 | $463.0M | $220.7M | ||
| Q2 24 | $427.3M | $205.0M | ||
| Q1 24 | $413.8M | $214.1M |
负债/权益比AVPTPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.7M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $29.0M | $14.4M |
| 自由现金流率自由现金流/营收 | 25.3% | 19.1% |
| 资本支出强度资本支出/营收 | 0.6% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.90× | — |
| 过去12个月自由现金流最近4个季度 | $81.6M | $41.7M |
8季度趋势，按日历期对齐
经营现金流AVPTPBYI
| Q4 25 | $29.7M | $14.4M | ||
| Q3 25 | $34.8M | $9.7M | ||
| Q2 25 | $20.3M | $14.1M | ||
| Q1 25 | $495.0K | $3.6M | ||
| Q4 24 | $32.8M | $15.6M | ||
| Q3 24 | $32.2M | $11.0M | ||
| Q2 24 | $16.2M | $1.0M | ||
| Q1 24 | $7.8M | $11.2M |
自由现金流AVPTPBYI
| Q4 25 | $29.0M | $14.4M | ||
| Q3 25 | $34.3M | $9.7M | ||
| Q2 25 | $19.3M | $14.1M | ||
| Q1 25 | $-1.0M | $3.6M | ||
| Q4 24 | $32.0M | $15.6M | ||
| Q3 24 | $30.8M | $11.0M | ||
| Q2 24 | $15.8M | $1.0M | ||
| Q1 24 | $7.3M | — |
自由现金流率AVPTPBYI
| Q4 25 | 25.3% | 19.1% | ||
| Q3 25 | 31.3% | 17.7% | ||
| Q2 25 | 18.9% | 26.8% | ||
| Q1 25 | -1.1% | 7.7% | ||
| Q4 24 | 35.9% | 26.4% | ||
| Q3 24 | 34.7% | 13.7% | ||
| Q2 24 | 20.2% | 2.1% | ||
| Q1 24 | 9.7% | — |
资本支出强度AVPTPBYI
| Q4 25 | 0.6% | 0.0% | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.9% | 0.0% | ||
| Q1 25 | 1.6% | 0.1% | ||
| Q4 24 | 0.8% | 0.0% | ||
| Q3 24 | 1.6% | 0.0% | ||
| Q2 24 | 0.5% | 0.0% | ||
| Q1 24 | 0.7% | 0.0% |
现金转化率AVPTPBYI
| Q4 25 | 1.90× | — | ||
| Q3 25 | 2.68× | 1.10× | ||
| Q2 25 | 7.01× | 2.41× | ||
| Q1 25 | 0.14× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.30× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVPT
| SAAS | $88.9M | 78% |
| Services | $14.7M | 13% |
| Termed License And Support | $10.1M | 9% |
PBYI
暂无分部数据
